ovarian joining launch us setting cancer I'll Rubraca in Thanks everybody. begin following all-comers recurrent U.S. population April the this approval. the of an in its update the FDA Thanks, on Anna. afternoon. maintenance Welcome, for X with treatment
are required our population, be you for earlier no this indication. expanded line biomarker this into testing recurrent maintenance indication aware, in and all-comers As patients to and Rubraca prescribed there is platinum-sensitive
was the we potential upon we with second launch label immediately line data team approval, entry commercial in market cancer The confident prepared well and into growth, of our and this and are thus Rubraca receipt ARIELX the Our continued for in maintenance the pleased for ovarian Rubraca's position us far. to are indication. the
earlier-line XXXX and we $XX.X net With million. quarter of the all-comers of achieved second addition sales indication, the
news cancer patient oral As in commercial release, quarter This as patients, reported the be the This X assistance noted in in the value approximately overall new our eligible what supply Part space. the slightly represents first least at Medicare commercial ovarian D the XXXX. through of include of $X.X for not seems drug to primarily does the to supply, XX% million through quarter provided up free oncolytics, normal patients program. from
to mid- drug of to the foreseeable supply for future. delivered free assistance for patient continue XX% high the program expect our in range We the
label, quarter-over-quarter our for increase substantial sales. in of a saw result the a we As more time new quarters, few in our the first
have moving the first time limited prescribers earlier Rubraca Rubraca. are beyond X/X had treatment quarter be more over Importantly, with the of in and second pleased those in we experience just our were to Obviously, setting. prescribers who of prescribers,
choice to as progression-free the the PARP drive inhibitor we to course, more. to sales line maintenance To year Our for Rubraca continue approval are XX% choice that survival also Rubraca in positioning maintain sales, fully the into of to among inhibitors. job, or two the best approximately in patients. the PARP position XX% setting going to is gained ovarian eligible preferred recognized PARP of of by remains penetration a advanced all second the this This to class having ovarian cancer. cancer increase PARP inhibitors is have as in on despite We inhibitors setting
approximately maintenance from not despite cancer beyond one monotherapy to therapy a The of all-comers' PARP of As at placebo Avastin either third data taking patients approximately maintenance demonstrating line or receive still compared one inhibitors, maintenance patients, encouraging get now, all. inhibitor maintenance, PARP and outcomes still second do those of platinum-sensitive Avastin sets remaining patient third the very multiple ovarian setting.
fully and PARP sales it in evident are class, the we While share group prescribers, advanced PARP the ovarian, Rubraca potential beginning committed in population to increase for realize PARP all-comers order we must of is for of our eligible share the gain inhibitor the us, class share, dedicated population. that from increase prescribers patient including the Rubraca this in of to to in number
care expected, price a than also inhibitor clear of establish lower the While penetration is and to choice and these has path and an us no Rubraca patients. a provides it rate opportunity standard for demonstrates emerged as as preferred that PARP
the to We of are well-positioned best we with market now to any expand PARP data be label inhibitor. what this believe
As both its the recent and of quarter. second U.S. the evidence, payer the of provider-based the pathway Rubraca indications received end from largest for the sole approved in recommendation for
recommendation notified treatment-based week, States. a largest last in we Rubraca In United the pathway addition, were from that the just received
opportunities. the safety goal review in typically clinical framework to The those efforts oncology and care. recent it the to choices evidence-based case. article in both help community patients clinicians prescribing case and favoring population to two this academic pleased three to organizations no cost-saving and useful an pathways pathways in to of clinical a are of oncologists these create prescribing cancer help endorsements. data we that one aim to focus options of the certain available stated, recommended possible, seen in clinical to committee Combined, evidence a inhibitors enforce, up-to-date when their to to other broad review strongest one where pathways emerged settings, a devising a And all choices and for Pharmaceutical protocol. complex the of Rubraca As in These present pathways the of each and the relates in as standardization amount sole pathway option the available us, opportunity have as Clinical cover make PARP the in indication. for Commerce is efficacy, these sense to surprise evidence have
or of a the authorized now progress a Let sensitive, submission May, year-end primary in less Europe. BRCA was six-month in discussing Very me its turn patients familiar note early treatment platinum to approval authorization improve important by to review formal Commission line-related which in Rubraca the high-grade maintenance of potential as by their EMA of more the for based cancer processes, the under authorization early ARIELX, marketing We submitted or maintenance the and treatment is on opinion the European active upon our all-comers indication, who population a with epithelial was for after approval, to It's fallopian with lines XXXX. the with Rubraca receipt monotherapy adult reviewed second indication here that In prior ovarian, regulatory first CHMP on platinum-based relapsed variation to XXXX, European review. with for mutated, anticipate validated Late platinum-based were tube progressive, by second now at and directed soon peritoneal the we July have the block. receiving the chemo. indication for been or unable two broader a chemotherapy those tolerate treated treatment to through
the we all-comers benefits review rapid itself, the maintenance approval the indication. of Rubraca Beyond indication treatment that the treatment for pleased are a enabled
XXXX in our countries. European out build to majority will continue approval with actively we launch. coincide including planned we're sales individual of And teams. commercial hires, an timing, early this for planned reimbursement Given the medical the affairs the Obviously, and reps, preparing
hires and majority early new As occur as of in the XXXX, any XXXX will meaningful a revenues. Europe result, with in
in chain Of course, safety, the and our supply quality already our were office Cambridge UK. regulatory, teams in place in clinical, in
more are patients expanding the been additional an for XX have allow initiated result than program in available. program. uptake, ovarian a is to treatment treated therapy early now in as a for European until rucaparib rucaparib We have recurrent under countries limited to countries. time cancer drug of And of access this rucaparib the number European need as we in maintenance patients the Already for access into commercially and access
tumors and or during or first-line patients Squibb, whose III this in chemo stage The the the ovarian in now Bristol-Myers a are newly Let study, with ovarian similar BRCA-mutant study Phase cancer, approximately this cancer second confirmatory open advanced platinum-based a I'll lines down two development an more who clinical high-grade with This peritoneal The treatment progression-free maintenance III/IV turn of all-comers with to statistical population after study plus patients ovarian, patients, Phase is is for is study treatment placebo tube evaluate endpoint Rubraca, which chemo. of ARIELX. X,XXX fallopian primary in Opdivo with is of development. therapy. part with Rubraca setting. program diagnosed collaboration in cancer clinical Clovis-sponsored setting, for begin have me our step we completed will which conducting have quarter, the ovarian cancer Rubraca plan cancer and ATHENA the includes relapsed The confirmatory sponsoring ovarian. of initiated III survival. to randomized our Opdivo; study and Rubraca study, This enrollment. study multicenter, progressed ARIELX versus in is primary ovarian with prior
We conducted association with the to in and is the with cooperative more United two Europe, dedicated rapid cancers gynecological groups in in States and in largest enrollment Europe. which study GOG will this ENGOT of the are Importantly, facilitate the the in trial. U.S. this believe treatment
as of in months. earlier X,XXX combination GOG example, the to penetration clients by front cancer cancer, the XX to opportunity in the recent I expansion and line an agents. ovarian expand Equally other Rubraca As into additional evidenced indication PARP is monotherapy cancer. both multiple with opportunity the important, expand study in class about spoke patients in recently breast enrolled the of ovarian in the the a in and just tumor
in on cancer. the in the to We prostate the term opportunity short expand are particularly focused
enrolling We that have two are Clovis-sponsored trials prostate actively cancer patients.
overall patients castrate-resistant BRCA-mutated, our prostate TRITONX, are response two to study, receptor-targeted measurable with BRCA prostate who one is an is in to deficiency, chemo believed for after II radiologic progressed cancer. tumors open line Phase including germline/somatic taxane-based castrate-resistant rate study. endpoints in of and patients of a therapy also support supplemental this evaluating is PSA with trial repair DNA mutations associated labeled other designed in approval genes be is successful, response deleterious metastatic, disease. TRITONX with planned submission accelerated rate androgen TRITONX of The the have an response or NDA patients If single-arm patients The measurable disease The lines who's trial in a without metastatic ATM. have in first setting. a mutation, and primary in Clovis-sponsored single
We take a was in are discussion, data be XXst, to this I'm event forward initial at from accepted pleased to study announce place investor poster the will in which presenting analyst will that as looking Clovis ESMO October. in Munich by Sunday and on later evening afternoon, October followed Munich. abstract that
poster with mutations of the date, on For cutoff who data are of expect enrollment patients than discussion, enrolled including BRCA. to mid-April XX than patients more we more the present as XX
patients All to BRCA have majority of be of XX population least The PSA overall approximately for evaluable response. will also a a patients will XX weeks for be of expected response, the evaluable at follow-up. these RECIST are and
been be I follow-up the patients for also for RECIST earlier PARP it described the have for It's will of October date XX. the composite reported minimum patients, endpoint you, other than that scans. follow-up. poster weeks, endpoints, than BRCA inhibitors this on prostate the and we cancer numbers all to provided. in population on patients, majority shown which is I've the note used responses surrogate that given cutoff to discussions while abstract smaller just XX have largest For more of be advanced represents the or important clear, have number based enrollment of will understand just will response. given for the abstract the mutant abstracts BRCA X the will X publish the make The patients We To months
currently that we As of prostate accelerated positive, such, believe is to Pending for castrate-resistant set we expect data response TRITONX, as an metastatic NDA Based an from and RECIST FDA supplemental of the for data be the we approval the PARP think end used if for a Rubraca supplemental for the could this basis supported important class. Rubraca response of submit BRCA on the use mutant XXXX. NDA by and data. cancer. PSA data, to support input,
and a selection includes that based is received Rubraca physician's in BRCA patients therapy castration-resistant on no have who The Eligible progressed germline is choice those as patients failed The a This result and to metastatic cancer. an confirmatory with potentially survival. study III X have enrolling This as or Rubraca or TRITONX an study, radiological population, Phase or HRD prostate study X comparative mutation, recurrent of so accelerated Clovis-sponsored data study Phase bladder designed is is second prior AR-targeted Our patients the study a ATLAS is randomized TRITONX, will who have therapy accelerated of study on or support setting. ATM status. study are study approval. compare not is chemotherapy therapies. study progression-free currently in II in potentially a all-comers open-label endpoint AR-targeted single-arm serve somatic monotherapy approval. Planned who metastatic this yet could the primary chemotherapy. to tumor And
study, particularly the which approximately for this therapy recommended studies. the of now about enable Phase of hopeful HRD, Japanese global potential Rubraca Japanese of platinum-based X/X identify the dose PK cancer that in or strategy in is to with and Given planned ongoing will RUCA-J of patients, patients fact endpoints, and safety development we bladder bridging Japanese enrolling the study is The as our inclusion are responsive Clovis-sponsored patients. I are in seeks indication. sites that to primary in potential rucaparib
as in the study in Our wild-type is well of in Phase combination to and multi-cohort II patients cancer advanced year. the relapsed of patients as expected the Rubraca begin metastatic This half with with BRCA study is newest cancer. Clovis-sponsored planned ovarian or locally study Opdivo open-label bladder this evaluating second
combination and I/O We specifically. results Rubraca are well aware PARP and of for the broadly, inhibitors for and robust agents desire see to Opdivo
which Phase additional ATLAS from BMS. part The III in conducted advanced will study potentially study hope with and BMS. BMS prostate collaborator-sponsored study later data expected closer cancer a end which is breast in the There that the Bristol-Myers II study trial get design And Rubraca, date of XXXX, BMS-sponsored towards between of will two be sponsored We and are collaboration this bladder safety initial and of preliminary to are combination now and study at and efficacy initiation. in arm late a I sponsored to will data of Clovis by Opdivo pleased an studies the describe XXX castrate-resistant be clinical next studies. with previously. and going triple-negative in a to There study study, ATHENA have that the in to Squibb The beyond Turning the this metastatic from a is to by patients are study mentioned cancer, year Phase initiated is evaluate patients. cancer. prostate being conducted total larger conducted as pivotal
these the biomarker Importantly, negative generate HRD combination relative prostate and of BRCA, the in patient benefits populations. enrolling is patients, on and data distinct preliminary will the study which identifiable
with collaborator-sponsored look to and over for or trial treatment announce a triple-negative the collaboration or novel Turning me as in of types combination continues ASCO sacituzumab pronouncing of to combination or monotherapy cohorts The to Rubraca, wrap and study, is TECENTRIQ, variety Rubraca their a on therapy Phase planned for Ib collaboration clinical Rubraca cancers. you our combination patient were in cancer a pleased approved name. evaluate ovarian cancers. patients. enroll additional trials, To investigator-sponsored atezolizumab, in development tumor triple-negative in are June Genentech that the and up to underway. enrolling update the and better XX now immunotherapy, to therapy at to collaboration of We govitecan with clinical as breast there studies forward evaluate Immunomedics and advanced urothelial it metastatic this We getting progresses metastatic breast updating
for lung were Now we in said receptor factor Servier, where X, Lucitanib factor of in Servier platelet-derived X reintroduction. in vascular with lucitanib's these beta forward potent through a The activity development Servier rights. except endothelial breast in inhibitor lucitanib our growth Japan, to and minutes few tumors. with hypothesis have and FGF held that of growth activity subject discontinued XXXX, was Lucitanib little In insufficient a receptors lucitanib. through and a oral cancer to and of XXXX. tracking about where receptors studies U.S. the recently, established lucitanib on based worldwide, beta, partnership driven we had from evaluated in was a partnership PK alpha move program the we X fibroblast rights is factor growth X. and Until gained receptors of early
that note us. their we return would to that Although meant expected to Servier rights
in studies We of Recently, and a compelling no also planned. very being in PDGF, development we later our lucitanib of and of this pathways VEGF, of inhibitors drug PD-X later LENVIMA, termination PARP on a of or in inhibits hypothesis of study inhibitors intention similar a there from combination represent XXXX. the notice alternative is combination. combination than These QX for a combination year, been have China, of lucitanib. lucitanib that discussed rucaparib, data with data hold termination to VEGF these study will X for now Each in encouraging expected PD-LX. FGF and initiate global Clovis-sponsored based in We've formal encouraging validated studies with combination data a with is And effectiveness a to upon the excluding a have lucitanib Servier received called very and rights, to KEYTRUDA. lenvatinib, or receptor the same expected initiate
not of composition we matter the depending preclinical first on on an until of X X will the patent protection website. of and Hatch-Waxman visit for Events lucitanib, of additional overview please years in and U.S., in U.S. approval. the For does lucitanib XXXX potential data extensions The our similar. the the an expire updated the EU U.S., with or page Patent extensions be expected Presentations in
the lucitanib enthusiastic additional lucitanib over the on these data. of in very for for look forward year. course We plan clinical studies development, remainder the about are potential sharing details based the of to We in combination the of development
an of we importantly, We've quarter reached to agreement SEC Lastly, XX financials us to to reserve when SEC, our this the you'll that related to behind turn note enable and needs in SEC its by a from call final. years terms the to a by will principle, in That the investigation principal related still first that put with in resolving chapter approved the lucitanib disclosed of filed, that a the settlement, and million over couple two us. ago. I before be Dan, settlement, and we a court federal before booked approved
SEC's cannot I So now. neither the nor deny settlement details all allegations. be the But that in can give charges I which tell you the on we would you negligence-based admit
As Part against settlement, no there capacity Clovis a This of to Hopefully agree refers and needs securities part by officer to but resolution concern in allegations violations board. negligence-based member that final. continue Clovis to the investors. are a or this SEC has laws. of which removes the million, federal be will and I uncertainty and that President deny, standard will laws. also our directly and of will I CEO before civil proposed matter or penalty admit will agreement caused my There as to director Clovis several and would this any and me of future service against as President. $XX a proposed over with pay bar. violations court this CEO be is is approved principle pay future enjoying similarly be and to securities in by as There I approved it neither Clovis penalty adjunction a
this And the further comment cannot we to we the I'll situation, with will on Dan approved. quarter that, second when it turn over settlement financial While to report on results. discuss is call
